KNSA - Kiniksa Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

898.6M

Cash

185M

Avg Qtr Burn

N/A

Short % of Float

13.04%

Insider Ownership

4.68%

Institutional Own.

96.35%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ARCALYST (Rilonacept) (IL-1α & IL-1β) Details Recurrent Pericarditis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vixarelimab (OSMRβ) (KPL-716) Details Skin disease/disorder, Prurigo nodularis	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KPL-404 (CD40) Details Autoimmune disease, Rheumatoid arthritis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavrilimumab (GM-CSFRa) Details Inflammatory disease, Giant cell arteritis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavrilimumab (GM-CSFRa) Details COVID-19, Pneumonia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.